Clinical Trials

Retina Consultants are actively involved in both local and international clinical trials.

These studies are important in measuring the outcomes of current treatments and improving patient eye disease management.

RIVAL
The objective is to investigate the difference between the risk of developing geographic atrophy following intravitreal Ranibizumab (Lucentis) relative to Aflibercept (Eylea) in patients with wet macular degeneration from baseline to month 24.Other measurements will be; the number of injections from baseline to month 24 the mean change in Best Corrected Visual Acuity (BCVA) from baseline to month 24.

The study is sponsored by Norvatis.

FLUID
This study will evaluate and compare two individualised Ranibizumab (Lucentis) treatment regimens. The aim will be to determine whether the presence some fluid associated with wet macular degeneration (ie. some residual activity of the wet macular degeneration) can be tolerated.

The study is sponsored by Norvatis

MACULA HOLE STUDY

The aim of the study is to present the visual results following macular hole surgery, and also to investigate the clinical course and results (anatomical and visual) of primary idiopathic macular hole eyes where primary surgery failed. Preliminary findings have been published in the May 2016 edition of Ophthalmology American Academy of Ophthalmology.

CONTROL STUDY
The Control study is a 24 month study looking at the role of Lucentis in the treatment of retinal swelling due to diabetic eye disease.

This study is sponsored by Norvatis